China Regenerative Medicine International Limited (8158) AI Stock Analysis

• Market Cap: HK$164.30M
• Dividend Yield: N/A
• Average Volume (3M): 55.39K
• Price to Earnings (P/E): 29.7
• Beta (1Y): -0.08
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 304,252,470
• 10 Day Avg. Volume: 53,325
• 30 Day Avg. Volume: 55,386
• PEG Ratio: -0.04
• Price to Book (P/B): 3.56
• Price to Sales (P/S): 0.99
• P/FCF Ratio: 5.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$0.53 ▲(19.77% Upside)

The overall stock score is primarily influenced by financial performance challenges, including high leverage and inconsistent cash flows. Technical analysis indicates neutral momentum, while valuation suggests the stock is relatively expensive. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Improved Profitability

Improved profitability in 2024 indicates better cost management and operational efficiency, which can enhance long-term financial stability.

Gross Profit Margin Increase

A significant increase in gross profit margin suggests effective cost control and pricing strategies, strengthening the company's competitive position.

Stockholders' Equity Improvement

Improvement in stockholders' equity reflects enhanced financial health, providing a stronger foundation for future growth and investment.

Negative Factors

High Leverage

High leverage can increase financial risk and limit the company's ability to invest in growth opportunities, affecting long-term sustainability.

Inconsistent Cash Flows

Inconsistent cash flows can hinder the company's ability to fund operations and growth initiatives, impacting financial flexibility and stability.

Revenue Volatility

Revenue volatility indicates challenges in maintaining consistent sales, which can affect long-term growth prospects and market confidence.

China Regenerative Medicine International Limited Business Overview & Revenue Model

Company Description

China Regenerative Medicine International Limited (8158) is a biotechnology company based in China that specializes in the research, development, and commercialization of regenerative medicine products and technologies. The company primarily focuses on stem cell therapies and tissue engineering, aiming to address various medical conditions and improve patient outcomes. Its core offerings include innovative treatments for orthopedic, cardiovascular, and neurological diseases, leveraging advancements in cellular therapy and biomaterials.

How the Company Makes Money

The company generates revenue primarily through the commercialization of its regenerative medicine products and therapies, which include stem cell treatments and related medical services. Key revenue streams include sales from its proprietary therapies, partnerships with healthcare institutions for clinical applications, and licensing agreements for its technology and products. Additionally, China Regenerative Medicine International Limited may benefit from government grants and funding for research and development in regenerative medicine, as well as collaborations with other biotech firms and research organizations to enhance its product offerings and market reach.

China Regenerative Medicine International Limited Financial Statement Overview

Summary

The company shows some recovery with improved profitability in 2024, but faces challenges such as revenue volatility, high leverage, and inconsistent cash flows. The high debt-to-equity ratio and zero cash flow in 2024 are significant concerns.

Income Statement

The company has shown improvement in recent years with a return to positive net income in 2024, following a significant loss in 2023. The gross profit margin increased from 27.9% in 2023 to 63.6% in 2024, indicating better cost management. However, revenue has been volatile, with a decline from 2022 to 2023 and a recovery in 2024, yet still below 2021 levels. This instability in revenue and profitability reflects ongoing challenges.

Balance Sheet

The debt-to-equity ratio is notably high at 2.13 in 2024, indicating significant leverage. Stockholders' equity has improved from 2023 to 2024, but remains a concern due to historical volatility. The equity ratio is low at 18.6%, suggesting limited financial cushion. The overall balance sheet reflects a company with high leverage and risk.

Cash Flow

The company reported zero operating and free cash flow in 2024, indicating potential liquidity issues. Despite positive operating cash flow in 2023, the lack of consistent free cash flow is concerning. The inability to sustain positive cash flows may limit growth opportunities and financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.22M	90.62M	69.49M	41.54M	282.90M	182.14M
Gross Profit	36.05M	57.65M	19.42M	37.62M	67.73M	41.81M
EBITDA	-13.31M	29.84M	-95.40M	14.44M	65.11M	-122.46M
Net Income	5.53M	17.75M	-107.70M	4.55M	51.83M	-404.23M
Balance Sheet
Total Assets	157.90M	135.71M	185.90M	275.91M	259.14M	152.49M
Cash, Cash Equivalents and Short-Term Investments	7.28M	57.45M	3.33M	1.85M	9.93M	4.77M
Total Debt	76.05M	53.69M	50.19M	72.01M	35.82M	43.19M
Total Liabilities	128.84M	110.51M	174.10M	172.00M	147.41M	207.64M
Stockholders Equity	29.06M	25.20M	11.79M	103.92M	111.73M	58.13M
Cash Flow
Free Cash Flow	2.35M	17.68M	6.06M	-20.25M	-3.83M	-397.74M
Operating Cash Flow	2.98M	18.30M	6.34M	-17.65M	-3.02M	-397.74M
Investing Cash Flow	-92.00K	-622.00K	-262.00K	-2.59M	9.27M	326.96M
Financing Cash Flow	-3.27M	2.37M	-7.36M	7.32M	-1.39M	67.37M

China Regenerative Medicine International Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8158, the sentiment is Negative. The current price of 0.44 is below the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.56, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.51 is Neutral, neither overbought nor oversold. The STOCH value of 53.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8158.

China Regenerative Medicine International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0690	66 Neutral	HK$720.81M	7.91	26.27%	2.29%	15.97%	-3.77%
2197	52 Neutral	HK$2.80B	-2.69	―	―	79.98%	-3.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1228	47 Neutral	HK$1.21B	-6.79	―	―	-40.24%	66.43%
2257	46 Neutral	HK$858.24M	―	―	―	―	83.89%
8158	45 Neutral	HK$164.30M	29.67	20.42%	―	―	―
6628	41 Neutral	HK$1.17B	―	-34.18%	―	-57.84%	24.58%